HomePaxilQuintiles projects increase in biopharma R&D spending
Posted in Paxil on 20th March 2014

Quintiles projects increase in biopharma R&D spending
Consider the trend for GlaxoSmithKline (NYSE: GSK), which entered the cliff slightly earlier than some others in Big Pharma. In 2006, a group of eight drugs – including Wellbutrin, Lamictal, Zofran and Paxil – made up 18 percent of all sales. By 2009 …
Read more on Triangle Business Journal

Related Post for The Hat Trick Of Parkinson's, Homelessness and Depression

Study links use of antidepressants Paxil and Prozac with birth defects
Pharmacological treatment of acute and chronic panic disorder
If Alkermes Plc Recover From high profile failures?
Latest Paxil News
The Hat Trick Of Parkinson's, Homelessness and Depression